Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR-2 Inhibitors
作者:Abdel-Ghany A. El-Helby、Rezk R. A. Ayyad、Helmy Sakr、Khaled El-Adl、Mamdouh M. Ali、Fathalla Khedr
DOI:10.1002/ardp.201700240
日期:2017.12
Novel series of phthalazine derivatives 6–11 were designed, synthesized, and evaluated for their anticancer activity against two human tumor cell lines, HCT‐116 human colon adenocarcinoma and MCF‐7 breast cancer cells, targeting the VEGFR‐2 enzyme. Compounds 7a,b and 8b,c showed the highest anticancer activities against both HCT116 human colon adenocarcinoma cells with IC50 of 6.04 ± 0.30, 13.22 ± 0
设计、合成了新型酞嗪衍生物 6-11 系列,并评估了它们对两种人类肿瘤细胞系 HCT-116 人结肠腺癌和 MCF-7 乳腺癌细胞的抗癌活性,这些细胞系靶向 VEGFR-2 酶。化合物 7a、b 和 8b、c 对 HCT116 人结肠腺癌细胞和 MCF-7 乳腺癌细胞均显示出最高的抗癌活性,IC50 分别为 6.04 ± 0.30、13.22 ± 0.22、18 ± 0.20 和 35 ± 0.45 μM与作为参考药物的索拉非尼相比,IC50 分别为 8.8 ± 0.45、17.9 ± 0.50、25.2 ± 0.55 和 44.3 ± 0.49 μM,IC50 分别为 5.47 ± 0.3 和 7.26 ± 0.3 μM。进一步评估了该系列中的 11 种化合物对 VEGFR-2 的抑制活性,其中化合物 7a、7b、8c、和 8b 也显示出最高的 VEGFR-2 抑制作用,IC50 分别为